Drugs / Ad4-Env150KN
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03878121 | Apr 2019 → Nov 2028 expected | — | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad4-Env150KN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03878121 ↗ |
| Route | Intranasal | “10\^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.” NCT03878121 ↗ |